Navigation Links
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
Date:11/19/2009

od of 2008 was primarily a result of the 2008 write-off of $1.9 million of deferred offering costs related to a delay in the Company's IPO. Also, in the 2009 period there were decreases in contract service costs associated with several of Omeros' clinical and preclinical programs and in clinical trial expenses due to the prior completion of enrollment in the Company's Phase 2 clinical study of OMS103HP for arthroscopic meniscectomy surgery.

Total operating expenses for the nine months ended September 30, 2009 were $16.5 million, compared to $19.1 million for the same period in 2008. The decrease in operating expenses in the nine months ended September 30, 2009 as compared to the same period of 2008 was primarily a result of items noted above.

Recent Highlights

  • Priced the Company's IPO on October 7, 2009, receiving net proceeds of approximately $61.8 million, and began trading on The NASDAQ Global Market under the ticker symbol "OMER" on October 8, 2009.
  • Announced positive results from the Phase 1/Phase 2 clinical trial of OMS302, Omeros' PharmacoSurgery product candidate being developed for use during ophthalmological procedures. OMS302 is a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis), each with well-known safety and pharmacologic profiles. The Phase 1/Phase 2 trial enrolled 61 patients undergoing age-related cataract extraction with lens replacement, and was designed to evaluate efficacy and safety of OMS302 added to a standard surgical irrigation solution. Data from this study showed that patients treated with OMS302 reported less postoperative pain and demonstrated statistically significant improvement in maintenance of mydriasis during the surgical procedure compared to patients treated with vehicle control.
  • Amended its agreement with Patobios Limited by which Omeros has the exclusive right to acquire
    '/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
9. Omeros Commences Initial Public Offering of Common Stock
10. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 “2014 Deep ... Industry” is a professional and in-depth research ... The report introduces Lubricant basic information, including ... structure and industry overview. This research covers ... market as well as global industry analysis ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Proove ... medicine, will be exhibiting data and research conducted through ... International Spine Intervention Society’s (ISIS) 22nd Annual Scientific ... at the Hyatt Regency, in Orlando, Florida. ... and clinical competence of physicians who care for patients ...
(Date:7/28/2014)... , July 28, 2014 /PRNewswire/ -   JOLT ... group of companies to join its growing portfolio of ... of Toronto,s JOLT accelerator, and ... on the roster. Since its launch ... have successfully raised  $7.5M of financing. Now at 23 ...
(Date:7/28/2014)... YORK , July 28, 2014  David ... ConvergeHEALTH by Deloitte , has been elected ... Interchange Standards Consortium, a non-profit working to establish ... data, particularly as it relates to electronic health ... continue CDISC,s mission of collaborating with organizations across ...
Breaking Biology Technology:Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3
... Osteotech, Inc.,(Nasdaq: OSTE ), a leader in ... today that revenue for the three months,ended September 30, ... three months ended September 30, 2007. The decline in ... primarily driven by a $2.8,million reduction in private label ...
... SHANGHAI, China, Nov. 7 /Xinhua-PRNewswire/ -- WuXi ... medical device research,and development outsourcing company with ... today that it has signed a new ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), ...
... are developing technologies that will fuel the continued growth ... financial boost through the 2008 Clean Tech Innovation Challenge. ... partnership between the City of San Diego, UC San ... San Diego State University (SDSU). The program is designed ...
Cached Biology Technology:Osteotech Reports 2008 Third Quarter Financial Results 2Osteotech Reports 2008 Third Quarter Financial Results 3Osteotech Reports 2008 Third Quarter Financial Results 4Osteotech Reports 2008 Third Quarter Financial Results 5WuXi PharmaTech Signs New Collaboration Agreement With Pfizer 2San Diego universities, government and industry rally around local Clean-Tech cluster 2San Diego universities, government and industry rally around local Clean-Tech cluster 3San Diego universities, government and industry rally around local Clean-Tech cluster 4San Diego universities, government and industry rally around local Clean-Tech cluster 5
(Date:7/28/2014)... led by the University of Arizona has sequenced the ... will enhance scientists, and agriculturalists, understanding of the growing ... development of new rice varieties that are better able ... global hunger challenges. , The paper, "The genome sequence ... for independent domestication," was published online in Nature ...
(Date:7/28/2014)... juvenile rat brain cells suggests that the effects of ... brain cells are temporary. , The study, published in ... , was conducted by biologists at the University of ... New York in response to concerns, arising from multiple ... children to general anesthetics may increase their susceptibility to ...
(Date:7/28/2014)... New research has identified areas of the Earth that ... climate change. , Europe is particularly vulnerable, as it ... four per cent, of any continent in ,refugia, ... natural environmental conditions remain relatively constant during times of ... Europe are mostly in Scandinavia and Scotland. , ...
Breaking Biology News(10 mins):Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2
... (DIYbio) community has grown, so have concerns among media ... DNA and manipulate life. In 2009, for example, ... the popular misconception: "In Attics and Closets, ,Biohackers, Discover ... survey of DIYbio practitioners (DIYers), the Synthetic Biology Project ...
... years ago, mammalian target of rapamycin or mTOR, a ... the antidepressant effects of ketamine, the first rapidly acting ... later, a group at the National Institutes of Mental ... receptor antagonist, also produced rapidly appearing antidepressant effects, similar ...
... APOPKA, FL--Shade nets are widely used in ornamental crop ... and birds. According to a 2011 study from the ... production in the United States occurred under shade or ... growers have begun experimenting with colored, gray, and white ...
Cached Biology News:First-ever survey of Do-It-Yourself Biology community challenges myths 2mTOR: A key brain signaling mechanism for rapidly acting antidepressants 2Shadehouses with photoselective nets featured in study of growing conditions 2
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
... 100%,S-Adenosyl Methionine 2.5%,Adenosine ... <0.1%,Cystathionine ... <0.1%,Glutathione ... Assay Range: 0.1 ug/ml to 1 mg/ml,(0.26 M to 2.6 mM) ...
Panomer 9 oligodeoxynucleotides are random primers that are labeled at the 5' end with our proprietary QSY 7 dye and they are useful for assessing microarray spot morphology, hybridization potential ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
Biology Products: